The Burden of Inflammatory Bowel Disease in Europe in 2020

Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Crohn's and colitis 2021-09, Vol.15 (9), p.1573-1587
Hauptverfasser: Zhao, Mirabella, Gönczi, Lóránt, Lakatos, Peter L, Burisch, Johan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1587
container_issue 9
container_start_page 1573
container_title Journal of Crohn's and colitis
container_volume 15
creator Zhao, Mirabella
Gönczi, Lóránt
Lakatos, Peter L
Burisch, Johan
description Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.
doi_str_mv 10.1093/ecco-jcc/jjab029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2489595633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ecco-jcc/jjab029</oup_id><sourcerecordid>2489595633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</originalsourceid><addsrcrecordid>eNptkDtPwzAUhS0EoqWwM6GMSCjUz9hmo6VApUosZbZc50YkSuJiN0L996QPEAPTPcM5n3Q_hK4JvidYszE459PKuXFV2RWm-gQNiZJZyrnUp_vMUq15NkAXMVYYCy2kOkcDxoSiitAhelh-QDLpQg5t4otk3ha1bRq78WGbTPwX1MlTGcFGSMo2mXXBr_eJYoov0Vlh6whXxztC78-z5fQ1Xby9zKePi9RxzjYp4cUKhBKaQU5wgbUUNMOZw7mykjAJUiupXJYLJXNOSCEpdkKSfq1ELgUbodsDdx38ZwdxY5oyOqhr24LvoqFc6f6xjLG-ig9VF3yMAQqzDmVjw9YQbHbGzM6Y6Y2Zo7F-cnOkd6sG8t_Bj6K-cHco-G79Ly79i_sGF9B1CA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489595633</pqid></control><display><type>article</type><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</creator><creatorcontrib>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</creatorcontrib><description>Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</description><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1093/ecco-jcc/jjab029</identifier><identifier>PMID: 33582812</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Adult ; Aged ; Colectomy - economics ; Colectomy - statistics &amp; numerical data ; Colitis, Ulcerative - economics ; Colitis, Ulcerative - epidemiology ; Colitis, Ulcerative - therapy ; Cost of Illness ; Crohn Disease - economics ; Crohn Disease - epidemiology ; Crohn Disease - therapy ; Europe - epidemiology ; Female ; Health Care Costs - statistics &amp; numerical data ; Hospitalization - economics ; Hospitalization - statistics &amp; numerical data ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Survival Rate ; Young Adult</subject><ispartof>Journal of Crohn's and colitis, 2021-09, Vol.15 (9), p.1573-1587</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</citedby><cites>FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</cites><orcidid>0000-0002-8392-4860 ; 0000-0002-3312-5139 ; 0000-0002-3948-6488</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33582812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Mirabella</creatorcontrib><creatorcontrib>Gönczi, Lóránt</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Burisch, Johan</creatorcontrib><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><title>Journal of Crohn's and colitis</title><addtitle>J Crohns Colitis</addtitle><description>Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</description><subject>Adult</subject><subject>Aged</subject><subject>Colectomy - economics</subject><subject>Colectomy - statistics &amp; numerical data</subject><subject>Colitis, Ulcerative - economics</subject><subject>Colitis, Ulcerative - epidemiology</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Cost of Illness</subject><subject>Crohn Disease - economics</subject><subject>Crohn Disease - epidemiology</subject><subject>Crohn Disease - therapy</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Health Care Costs - statistics &amp; numerical data</subject><subject>Hospitalization - economics</subject><subject>Hospitalization - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkDtPwzAUhS0EoqWwM6GMSCjUz9hmo6VApUosZbZc50YkSuJiN0L996QPEAPTPcM5n3Q_hK4JvidYszE459PKuXFV2RWm-gQNiZJZyrnUp_vMUq15NkAXMVYYCy2kOkcDxoSiitAhelh-QDLpQg5t4otk3ha1bRq78WGbTPwX1MlTGcFGSMo2mXXBr_eJYoov0Vlh6whXxztC78-z5fQ1Xby9zKePi9RxzjYp4cUKhBKaQU5wgbUUNMOZw7mykjAJUiupXJYLJXNOSCEpdkKSfq1ELgUbodsDdx38ZwdxY5oyOqhr24LvoqFc6f6xjLG-ig9VF3yMAQqzDmVjw9YQbHbGzM6Y6Y2Zo7F-cnOkd6sG8t_Bj6K-cHco-G79Ly79i_sGF9B1CA</recordid><startdate>20210925</startdate><enddate>20210925</enddate><creator>Zhao, Mirabella</creator><creator>Gönczi, Lóránt</creator><creator>Lakatos, Peter L</creator><creator>Burisch, Johan</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8392-4860</orcidid><orcidid>https://orcid.org/0000-0002-3312-5139</orcidid><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid></search><sort><creationdate>20210925</creationdate><title>The Burden of Inflammatory Bowel Disease in Europe in 2020</title><author>Zhao, Mirabella ; Gönczi, Lóránt ; Lakatos, Peter L ; Burisch, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-14fbe58593ed10f09752606c0d8a7137e79878c6d587d411f720c571c4485d753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Colectomy - economics</topic><topic>Colectomy - statistics &amp; numerical data</topic><topic>Colitis, Ulcerative - economics</topic><topic>Colitis, Ulcerative - epidemiology</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Cost of Illness</topic><topic>Crohn Disease - economics</topic><topic>Crohn Disease - epidemiology</topic><topic>Crohn Disease - therapy</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Health Care Costs - statistics &amp; numerical data</topic><topic>Hospitalization - economics</topic><topic>Hospitalization - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Mirabella</creatorcontrib><creatorcontrib>Gönczi, Lóránt</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Burisch, Johan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Mirabella</au><au>Gönczi, Lóránt</au><au>Lakatos, Peter L</au><au>Burisch, Johan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Burden of Inflammatory Bowel Disease in Europe in 2020</atitle><jtitle>Journal of Crohn's and colitis</jtitle><addtitle>J Crohns Colitis</addtitle><date>2021-09-25</date><risdate>2021</risdate><volume>15</volume><issue>9</issue><spage>1573</spage><epage>1587</epage><pages>1573-1587</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><abstract>Abstract New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10–30% of CD and 5–10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>33582812</pmid><doi>10.1093/ecco-jcc/jjab029</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-8392-4860</orcidid><orcidid>https://orcid.org/0000-0002-3312-5139</orcidid><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1873-9946
ispartof Journal of Crohn's and colitis, 2021-09, Vol.15 (9), p.1573-1587
issn 1873-9946
1876-4479
language eng
recordid cdi_proquest_miscellaneous_2489595633
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Adult
Aged
Colectomy - economics
Colectomy - statistics & numerical data
Colitis, Ulcerative - economics
Colitis, Ulcerative - epidemiology
Colitis, Ulcerative - therapy
Cost of Illness
Crohn Disease - economics
Crohn Disease - epidemiology
Crohn Disease - therapy
Europe - epidemiology
Female
Health Care Costs - statistics & numerical data
Hospitalization - economics
Hospitalization - statistics & numerical data
Humans
Incidence
Male
Middle Aged
Prevalence
Survival Rate
Young Adult
title The Burden of Inflammatory Bowel Disease in Europe in 2020
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A27%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Burden%20of%20Inflammatory%20Bowel%20Disease%20in%20Europe%20in%202020&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Zhao,%20Mirabella&rft.date=2021-09-25&rft.volume=15&rft.issue=9&rft.spage=1573&rft.epage=1587&rft.pages=1573-1587&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1093/ecco-jcc/jjab029&rft_dat=%3Cproquest_cross%3E2489595633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489595633&rft_id=info:pmid/33582812&rft_oup_id=10.1093/ecco-jcc/jjab029&rfr_iscdi=true